Bassil Dahiyat - Xencor Co-Founder, CEO and President and Director
| XNCR Stock | USD 24.13 0.12 0.50% |
CEO
Dr. Bassil I. Dahiyat Ph.D. is a President, Chief Executive Officer, Founder and Director of the Company. Dr. Dahiyat has served as our President and Chief Executive Officer since February 2005 and as a member of our Board of Directors since August 1997. Dr. Dahiyat cofounded Xencor in 1997 and, from 1997 to 2003, served as our Chief Executive Officer and, from 2003 to 2005, served as our Chief Scientific Officer. Dr. Dahiyat currently serves on the board of directors of Kodiak Sciences Inc., a publicly traded company. In 2005, Dr. Dahiyat was recognized as a technology pioneer by the World Economic Forum. Additionally, Dr. Dahiyat was named one of 2003 Top 100 Young Innovators by MIT Technology Review magazine for his work on protein design and its development for therapeutic applications and has received awards from the American Chemical Society, the Controlled Release Society and the California Institute of Technology since 2015.
| Age | 54 |
| Tenure | 9 years |
| Address | 465 North Halstead Street, Pasadena, CA, United States, 91107 |
| Phone | 626 305 5900 |
| Web | https://www.xencor.com |
Bassil Dahiyat Latest Insider Activity
Tracking and analyzing the buying and selling activities of Bassil Dahiyat against Xencor stock is an integral part of due diligence when investing in Xencor. Bassil Dahiyat insider activity provides valuable insight into whether Xencor is net buyers or sellers over its current business cycle. Note, Xencor insiders must abide by specific rules, including filing SEC forms every time they buy or sell Xencor'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Bassil Dahiyat over three weeks ago Disposition of 13548 shares by Bassil Dahiyat of Xencor at 15.69 subject to Rule 16b-3 | ||
Bassil Dahiyat over three weeks ago Disposition of 49278 shares by Bassil Dahiyat of Xencor at 15.69 subject to Rule 16b-3 | ||
Bassil Dahiyat over six months ago Disposition of 76012 shares by Bassil Dahiyat of Xencor at 4.25 subject to Rule 16b-3 | ||
Bassil Dahiyat over six months ago Disposition of 2602 shares by Bassil Dahiyat of Xencor at 29.8793 subject to Rule 16b-3 |
Xencor Management Efficiency
The company has return on total asset (ROA) of (0.1524) % which means that it has lost $0.1524 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2902) %, meaning that it created substantial loss on money invested by shareholders. Xencor's management efficiency ratios could be used to measure how well Xencor manages its routine affairs as well as how well it operates its assets and liabilities. As of 12/20/2024, Return On Tangible Assets is likely to drop to -0.14. In addition to that, Return On Capital Employed is likely to grow to -0.15. At this time, Xencor's Non Current Assets Total are relatively stable compared to the past year. As of 12/20/2024, Non Currrent Assets Other is likely to grow to about 1.1 M, while Total Current Assets are likely to drop slightly above 326.5 M.Similar Executives
| Found 9 records | CEO Age | ||
| Carole MD | Larimar Therapeutics | 65 | |
| Alexandria Forbes | MeiraGTx Holdings PLC | 59 | |
| Kevin Koch | Edgewise Therapeutics | 64 | |
| Robert Coffin | Replimune Group | 59 | |
| Markus MD | Monte Rosa Therapeutics | 53 | |
| Jon Congleton | Mineralys Therapeutics, Common | 61 | |
| James Porter | Nuvalent | 48 | |
| Dinesh Patel | Protagonist Therapeutics | 67 | |
| MBA JD | Viridian Therapeutics | 54 | |
Management Performance
| Return On Equity | -0.29 | ||||
| Return On Asset | -0.15 |
Xencor Inc Leadership Team
Elected by the shareholders, the Xencor's board of directors comprises two types of representatives: Xencor inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Xencor. The board's role is to monitor Xencor's management team and ensure that shareholders' interests are well served. Xencor's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Xencor's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Nancy MD, Executive Officer | ||
| Dane CFA, Senior Strategy | ||
| Jennifer Sandoz, Senior Resources | ||
| John Desjarlais, Chief Scientific Officer and Sr. VP of Research | ||
| Bart Cornelissen, Senior CFO | ||
| Bassil Dahiyat, Co-Founder, CEO and President and Director | ||
| Kirk RAC, Senior Assurance | ||
| John Kuch, VP of Fin. | ||
| Eric Kowack, Senior Management | ||
| Jeremy Grunstein, Vice President of Business Development | ||
| Celia JD, General VP | ||
| Charles Liles, Associate Relations |
Xencor Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Xencor a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.29 | ||||
| Return On Asset | -0.15 | ||||
| Profit Margin | (2.33) % | ||||
| Operating Margin | (5.82) % | ||||
| Current Valuation | 1.2 B | ||||
| Shares Outstanding | 69.98 M | ||||
| Shares Owned By Insiders | 0.89 % | ||||
| Shares Owned By Institutions | 99.11 % | ||||
| Number Of Shares Shorted | 4.46 M | ||||
| Price To Earning | 69.81 X |
Pair Trading with Xencor
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Xencor position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Xencor will appreciate offsetting losses from the drop in the long position's value.Moving together with Xencor Stock
Moving against Xencor Stock
| 0.9 | VALN | Valneva SE ADR | PairCorr |
| 0.86 | PFE | Pfizer Inc Aggressive Push | PairCorr |
| 0.83 | ERNA | Eterna Therapeutics | PairCorr |
| 0.76 | LLY | Eli Lilly | PairCorr |
| 0.76 | GNFT | Genfit | PairCorr |
The ability to find closely correlated positions to Xencor could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Xencor when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Xencor - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Xencor Inc to buy it.
The correlation of Xencor is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Xencor moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Xencor Inc moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Xencor can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Xencor Stock Analysis
When running Xencor's price analysis, check to measure Xencor's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Xencor is operating at the current time. Most of Xencor's value examination focuses on studying past and present price action to predict the probability of Xencor's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Xencor's price. Additionally, you may evaluate how the addition of Xencor to your portfolios can decrease your overall portfolio volatility.